AIHOT
内容
精选全部 AI 动态AI 日报主题收藏
接入
Agent 接入
更多
关于更新日志反馈
内部员工登录
精选全部日报更多
内部员工登录
原文
Rohan Paul@rohanpaul_ai
67
2026-07-04 23:35·6小时前
AI 摘要

Anthropic 宣布推出 Claude Science，旨在像 Claude Code 改变编程那样革新实验室研究。药物发现过程充满不确定性，分子常因生物学、化学、安全性或剂量问题失败。Anthropic 让自家研究人员直接体验这种失败并反馈到产品设计中。首批项目聚焦被忽视疾病，包括罕见遗传病和部分热带病。罕见病通常由单个基因突变引发，为 AI 提供更清晰的靶点，而常见病则涉及多基因、组织与环境的复杂交互。Anthropic 选择这类领域以避开与大型制药客户的竞争。公司已收购 Coefficient Bio，并聘请原 AlphaFold 研究员 John Jumper，表明生物学并非副业。

Anthropic wants to make its own drugs with help from Claude.

Claude Science is meant to do for lab research what Claude Code did for programming.

Drug discovery is messier， because molecules fail when biology， chemistry， safety， or dosing breaks.

Anthropic wants its researchers to feel those failures directly while shaping the product.

The first programs will target neglected diseases， including rare disorders and some tropical conditions.

These areas often have clearer biology but weaker commercial incentives than common diseases.

Many rare genetic disorders start with one broken gene， giving AI a cleaner target.

Common conditions usually involve many genes， tissues， histories， and environments interacting at once.

That difference makes early rare-disease work a harder business， but a clearer testbed.

Anthropic also avoids competing with pharma customers by choosing overlooked programs.

Anthropic already works closely with major drugmakers， so it understands where researchers get stuck.

Novartis CEO Vas Narasimhan joining the board gives those product decisions direct pharma-level pressure.

Anthropic bought Coefficient Bio and hired AlphaFold researcher John Jumper， so this is not a side experiment. Shows how seriously Anthropic is treating biology.

---

statnews. com/2026/06/30/anthropic-ai-drug-development/

Rohan Paul@rohanpaul_ai · X
67导出 Markdown
2026-07-04 23:35·6小时前
在 X 看原推· x.com
AI 摘要

Anthropic 宣布推出 Claude Science，旨在像 Claude Code 改变编程那样革新实验室研究。药物发现过程充满不确定性，分子常因生物学、化学、安全性或剂量问题失败。Anthropic 让自家研究人员直接体验这种失败并反馈到产品设计中。首批项目聚焦被忽视疾病，包括罕见遗传病和部分热带病。罕见病通常由单个基因突变引发，为 AI 提供更清晰的靶点，而常见病则涉及多基因、组织与环境的复杂交互。Anthropic 选择这类领域以避开与大型制药客户的竞争。公司已收购 Coefficient Bio，并聘请原 AlphaFold 研究员 John Jumper，表明生物学并非副业。

Anthropic wants to make its own drugs with help from Claude.

Claude Science is meant to do for lab research what Claude Code did for programming.

Drug discovery is messier， because molecules fail when biology， chemistry， safety， or dosing breaks.

Anthropic wants its researchers to feel those failures directly while shaping the product.

The first programs will target neglected diseases， including rare disorders and some tropical conditions.

Anthropic推理行业动态
在 X 查看原推导出 Markdown

These areas often have clearer biology but weaker commercial incentives than common diseases.

Many rare genetic disorders start with one broken gene， giving AI a cleaner target.

Common conditions usually involve many genes， tissues， histories， and environments interacting at once.

That difference makes early rare-disease work a harder business， but a clearer testbed.

Anthropic also avoids competing with pharma customers by choosing overlooked programs.

Anthropic already works closely with major drugmakers， so it understands where researchers get stuck.

Novartis CEO Vas Narasimhan joining the board gives those product decisions direct pharma-level pressure.

Anthropic bought Coefficient Bio and hired AlphaFold researcher John Jumper， so this is not a side experiment. Shows how seriously Anthropic is treating biology.

---

statnews. com/2026/06/30/anthropic-ai-drug-development/

Anthropic推理行业动态
在 X 查看原推x.com